Longitudinal profiling of serum ADAM17 across clinical stages in multiple myeloma: a dynamic biomarker and its association with T cell alterations

Key Points

• ADAM17 serves as a dynamic biomarker reflecting tumor development and renal function damage.
• ADAM17 levels correlate with clinical stages, enhancing prognostic tools for multiple myeloma.
• The use of ADAM17 may improve personalized treatment plans for patients by enabling timely interventions.
• Strengthening current risk algorithms with ADAM17 could potentially offer more precise prognostic insights.

Abstract